ABSTRACT
One major challenge in multiple sclerosis is to understand the cellular and molecular mechanisms leading to disease severity progression. The recently demonstrated correlation between disease severity and remyelination emphasizes the importance of identifying factors leading to a favourable outcome. Why remyelination fails or succeeds in multiple sclerosis patients remains largely unknown, mainly because remyelination has never been studied within a humanized pathological context that would recapitulate major events in plaque formation such as infiltration of inflammatory cells. Therefore, we developed a new paradigm by grafting healthy donor or multiple sclerosis patient lymphocytes in the demyelinated lesion of nude mice spinal cord. We show that lymphocytes play a major role in remyelination whose efficacy is significantly decreased in mice grafted with multiple sclerosis lymphocytes compared to those grafted with healthy donors lymphocytes. Mechanistically, we demonstrated in vitro that lymphocyte-derived mediators influenced differentiation of oligodendrocyte precursor cells through a crosstalk with microglial cells. Among mice grafted with lymphocytes from different patients, we observed diverse remyelination patterns reproducing for the first time the heterogeneity observed in multiple sclerosis patients. Comparing lymphocyte secretory profile from patients exhibiting high and low remyelination ability, we identified novel molecules involved in oligodendrocyte precursor cell differentiation and validated CCL19 as a target to improve remyelination. Specifically, exogenous CCL19 abolished oligodendrocyte precursor cell differentiation observed in patients with high remyelination pattern. Multiple sclerosis lymphocytes exhibit intrinsic capacities to coordinate myelin repair and further investigation on patients with high remyelination capacities will provide new pro-regenerative strategies.
Subject(s)
Adaptive Immunity/physiology , Demyelinating Diseases/immunology , Myelin Sheath/immunology , Adolescent , Adult , Aged , Animals , Cell Transplantation , Chemokine CCL19/immunology , Female , Humans , Lymphocytes/immunology , Lysophosphatidylcholines/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Nude , Middle Aged , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Neural Stem Cells/immunology , Oligodendroglia/immunology , Oligodendroglia/pathology , Young AdultABSTRACT
A concern for researchers planning multisite studies is that scanner and T1-weighted sequence-related biases on regional volumes could overshadow true effects, especially for studies with a heterogeneous set of scanners and sequences. Current approaches attempt to harmonize data by standardizing hardware, pulse sequences, and protocols, or by calibrating across sites using phantom-based corrections to ensure the same raw image intensities. We propose to avoid harmonization and phantom-based correction entirely. We hypothesized that the bias of estimated regional volumes is scaled between sites due to the contrast and gradient distortion differences between scanners and sequences. Given this assumption, we provide a new statistical framework and derive a power equation to define inclusion criteria for a set of sites based on the variability of their scaling factors. We estimated the scaling factors of 20 scanners with heterogeneous hardware and sequence parameters by scanning a single set of 12 subjects at sites across the United States and Europe. Regional volumes and their scaling factors were estimated for each site using Freesurfer's segmentation algorithm and ordinary least squares, respectively. The scaling factors were validated by comparing the theoretical and simulated power curves, performing a leave-one-out calibration of regional volumes, and evaluating the absolute agreement of all regional volumes between sites before and after calibration. Using our derived power equation, we were able to define the conditions under which harmonization is not necessary to achieve 80% power. This approach can inform choice of processing pipelines and outcome metrics for multisite studies based on scaling factor variability across sites, enabling collaboration between clinical and research institutions.
Subject(s)
Artifacts , Brain/anatomy & histology , Image Interpretation, Computer-Assisted/instrumentation , Image Interpretation, Computer-Assisted/methods , Magnetic Resonance Imaging/instrumentation , Magnetic Resonance Imaging/methods , Models, Statistical , Algorithms , Computer Simulation , Equipment Design , Equipment Failure Analysis , Europe , Humans , Image Enhancement/instrumentation , Image Enhancement/methods , Reproducibility of Results , Sensitivity and Specificity , United StatesABSTRACT
A recent genome-wide association study reported five loci for which there was strong, but sub-genome-wide significant evidence for association with multiple sclerosis risk. The aim of this study was to evaluate the role of these potential risk loci in a large and independent data set of ≈ 20,000 subjects. We tested five single nucleotide polymorphisms rs228614 (MANBA), rs630923 (CXCR5), rs2744148 (SOX8), rs180515 (RPS6KB1), and rs6062314 (ZBTB46) for association with multiple sclerosis risk in a total of 8499 cases with multiple sclerosis, 8765 unrelated control subjects and 958 trios of European descent. In addition, we assessed the overall evidence for association by combining these newly generated data with the results from the original genome-wide association study by meta-analysis. All five tested single nucleotide polymorphisms showed consistent and statistically significant evidence for association with multiple sclerosis in our validation data sets (rs228614: odds ratio = 0.91, P = 2.4 × 10(-6); rs630923: odds ratio = 0.89, P = 1.2 × 10(-4); rs2744148: odds ratio = 1.14, P = 1.8 × 10(-6); rs180515: odds ratio = 1.12, P = 5.2 × 10(-7); rs6062314: odds ratio = 0.90, P = 4.3 × 10(-3)). Combining our data with results from the previous genome-wide association study by meta-analysis, the evidence for association was strengthened further, surpassing the threshold for genome-wide significance (P < 5 × 10(-8)) in each case. Our study provides compelling evidence that these five loci are genuine multiple sclerosis susceptibility loci. These results may eventually lead to a better understanding of the underlying disease pathophysiology.
Subject(s)
Multiple Sclerosis/genetics , Receptors, CXCR5/genetics , Ribosomal Protein S6 Kinases, 70-kDa/genetics , SOXE Transcription Factors/genetics , Transcription Factors/genetics , alpha-Mannosidase/genetics , Case-Control Studies , Databases, Genetic , Female , Genetic Loci/genetics , Genetic Predisposition to Disease/genetics , Humans , Male , Multiple Sclerosis/diagnosis , Polymorphism, Single Nucleotide/geneticsABSTRACT
Restless legs syndrome (RLS) is a sensorimotor disorder with an age-dependent prevalence of up to 10% in the general population above 65 years of age. Affected individuals suffer from uncomfortable sensations and an urge to move in the lower limbs that occurs mainly in resting situations during the evening or at night. Moving the legs or walking leads to an improvement of symptoms. Concomitantly, patients report sleep disturbances with consequences such as reduced daytime functioning. We conducted a genome-wide association study (GWA) for RLS in 922 cases and 1,526 controls (using 301,406 SNPs) followed by a replication of 76 candidate SNPs in 3,935 cases and 5,754 controls, all of European ancestry. Herein, we identified six RLS susceptibility loci of genome-wide significance, two of them novel: an intergenic region on chromosome 2p14 (rs6747972, Pâ=â9.03 × 10(-11), ORâ=â1.23) and a locus on 16q12.1 (rs3104767, Pâ=â9.4 × 10(-19), ORâ=â1.35) in a linkage disequilibrium block of 140 kb containing the 5'-end of TOX3 and the adjacent non-coding RNA BC034767.
Subject(s)
Chromosomes, Human, Pair 16/genetics , Chromosomes, Human, Pair 2/genetics , Genetic Loci/genetics , Genetic Predisposition to Disease/genetics , Genome-Wide Association Study , Restless Legs Syndrome/genetics , Humans , Polymorphism, Single Nucleotide/genetics , Reproducibility of Results , Risk FactorsABSTRACT
BACKGROUND: Single nucleotide polymorphisms (SNPs) rs429358 (ε4) and rs7412 (ε2), both invoking changes in the amino-acid sequence of the apolipoprotein E (APOE) gene, have previously been tested for association with multiple sclerosis (MS) risk. However, none of these studies was sufficiently powered to detect modest effect sizes at acceptable type-I error rates. As both SNPs are only imperfectly captured on commonly used microarray genotyping platforms, their evaluation in the context of genome-wide association studies has been hindered until recently. METHODS: We genotyped 12 740 subjects hitherto not studied for their APOE status, imputed raw genotype data from 8739 subjects from five independent genome-wide association studies datasets using the most recent high-resolution reference panels, and extracted genotype data for 8265 subjects from previous candidate gene assessments. RESULTS: Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs, our analyses did not support a role of rs429358 or rs7412 on MS susceptibility. This included meta-analyses of the combined data across 13 913 MS cases and 15 831 controls (OR=0.95, p=0.259, and OR 1.07, p=0.0569, for rs429358 and rs7412, respectively). CONCLUSION: Given the large sample size of our analyses, it is unlikely that the two APOE missense SNPs studied here exert any relevant effects on MS susceptibility.
Subject(s)
Apolipoproteins E/genetics , Genetic Association Studies , Genetic Predisposition to Disease , Multiple Sclerosis/genetics , Databases, Genetic , Humans , Polymorphism, Single Nucleotide/genetics , Risk Factors , White People/geneticsABSTRACT
The tyrosine kinase 2 variant rs34536443 has been established as a genetic risk factor for multiple sclerosis in a variety of populations. However, the functional effect of this variant on disease pathogenesis remains unclear. This study replicated the genetic association of tyrosine kinase 2 with multiple sclerosis in a cohort of 1366 French patients and 1802 controls. Furthermore, we assessed the functional consequences of this polymorphism on human T lymphocytes by comparing the reactivity and cytokine profile of T lymphocytes isolated from individuals expressing the protective TYK2(GC) genotype with the disease-associated TYK2(GG) genotype. Our results demonstrate that the protective C allele infers decreased tyrosine kinase 2 activity, and this reduction of activity is associated with a shift in the cytokine profile favouring the secretion of Th2 cytokines. These findings suggest that the rs34536443 variant effect on multiple sclerosis susceptibility might be mediated by deviating T lymphocyte differentiation toward a Th2 phenotype. This impact of tyrosine kinase 2 on effector differentiation is likely to be of wider importance because other autoimmune diseases also have been associated with polymorphisms within tyrosine kinase 2. The modulation of tyrosine kinase 2 activity might therefore represent a new therapeutic approach for the treatment of autoimmune diseases.
Subject(s)
Genetic Predisposition to Disease , Multiple Sclerosis/genetics , Multiple Sclerosis/pathology , Polymorphism, Single Nucleotide/genetics , T-Lymphocytes/physiology , TYK2 Kinase/genetics , Adolescent , Adult , Case-Control Studies , Cell Proliferation , Cells, Cultured , Chi-Square Distribution , Cytokines/metabolism , Female , Flow Cytometry , France/epidemiology , GATA3 Transcription Factor/genetics , GATA3 Transcription Factor/metabolism , Gene Expression Regulation/genetics , Genotype , Humans , Male , Models, Molecular , Signal Transduction/drug effects , Signal Transduction/genetics , T-Lymphocytes/drug effects , Time Factors , Young AdultSubject(s)
Ankyrin Repeat , Carrier Proteins/genetics , Genome-Wide Association Study , Multiple Sclerosis/genetics , Adult , Case-Control Studies , Databases, Genetic , Female , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide , White People/geneticsABSTRACT
By combining all the data available from the Genetic Analysis of Multiple sclerosis in EuropeanS (GAMES) project, we have been able to identify 17 microsatellite markers showing consistent evidence for apparent association. As might be expected five of these markers map within the Major Histocompatibility Complex (MHC) and are in LD with HLA-DRB1. Individual genotyping of the 12 non-MHC markers confirmed association for three of them--D11S1986, D19S552 and D20S894. Association mapping across the candidate genes implicated by these markers in 937 UK trio families revealed modestly associated haplotypes in JAG1 (p=0.019) on chromosome 20p12.2 and POU2AF1 (p=0.003) on chromosome 11q23.1.
Subject(s)
Calcium-Binding Proteins/genetics , Genetic Predisposition to Disease , Genetic Testing , Intercellular Signaling Peptides and Proteins/genetics , Linkage Disequilibrium/genetics , Membrane Proteins/genetics , Multiple Sclerosis/genetics , Trans-Activators/genetics , Europe/epidemiology , Female , Genotype , Humans , Jagged-1 Protein , Male , Microsatellite Repeats , Multiple Sclerosis/epidemiology , Serrate-Jagged ProteinsABSTRACT
Multiple sclerosis (MS) is a prevalent neurological disease of complex etiology. Here, we describe the characterization of a multi-incident MS family that nominated a rare missense variant (p.G420D) in plasminogen (PLG) as a putative genetic risk factor for MS. Genotyping of PLG p.G420D (rs139071351) in 2160 MS patients, and 886 controls from Canada, identified 10 additional probands, two sporadic patients and one control with the variant. Segregation in families harboring the rs139071351 variant, identified p.G420D in 26 out of 30 family members diagnosed with MS, 14 unaffected parents, and 12 out of 30 family members not diagnosed with disease. Despite considerably reduced penetrance, linkage analysis supports cosegregation of PLG p.G420D and disease. Genotyping of PLG p.G420D in 14446 patients, and 8797 controls from Canada, France, Spain, Germany, Belgium, and Austria failed to identify significant association with disease (P = 0.117), despite an overall higher prevalence in patients (OR = 1.32; 95% CI = 0.93-1.87). To assess whether additional rare variants have an effect on MS risk, we sequenced PLG in 293 probands, and genotyped all rare variants in cases and controls. This analysis identified nine rare missense variants, and although three of them were exclusively observed in MS patients, segregation does not support pathogenicity. PLG is a plausible biological candidate for MS owing to its involvement in immune system response, blood-brain barrier permeability, and myelin degradation. Moreover, components of its activation cascade have been shown to present increased activity or expression in MS patients compared to controls; further studies are needed to clarify whether PLG is involved in MS susceptibility.
Subject(s)
Chromosomes, Human, Pair 6/chemistry , Multiple Sclerosis/genetics , Plasminogen/genetics , Polymorphism, Single Nucleotide , Adult , Aged , Amino Acid Sequence , Case-Control Studies , Chromosomes, Human, Pair 6/metabolism , Exome , Female , Gene Expression , Genotype , Humans , Male , Middle Aged , Multiple Sclerosis/pathology , Pedigree , Risk Factors , Sequence Alignment , Sequence Homology, Amino AcidABSTRACT
We report the results of a genome-wide screen for linkage disequilibrium (LD) in multiple sclerosis (MS) performed on 200 cases, 200 controls and 200 case-parent trios from France employing pooled DNA methodology. A total of 3510 microsatellite markers supplied through the GAMES collaborative were analysed and ranked according to their evidence for association. The most promising 117 markers were then followed up in a two-step validation process. In the first step, additional PCR of the DNA pools was performed in order to refine the ranking order. In the second step, markers were genotyped in individual cases and parents from the trio families. Seven markers showing nominally significant allele frequency differences between affected and unaffected emerged-D6S265, D12S1064, TNFa, D7S1824, D14S1426, D14S605 and D21S2051. These potential associations will require confirmation in further studies.
Subject(s)
Genetic Testing/methods , Multiple Sclerosis/genetics , Alleles , Case-Control Studies , France/epidemiology , Gene Frequency , Genetic Testing/statistics & numerical data , Genome, Human , Genotype , Humans , International Cooperation , Linkage Disequilibrium , Microsatellite Repeats , Multiple Sclerosis/epidemiology , Prospective StudiesABSTRACT
A recent investigation reported, for the first time, an association between variants in the IFIH1-GCA-KCNH7 locus and multiple sclerosis (MS). We sought to replicate this genetic association in MS with a new independent MS cohort composed of French Caucasian MS trio families. The two most significant IFIH1 single nucleotide polymorphisms, rs1990760 and rs2068330, reported as involved in MS susceptibility, were genotyped in 591 French Caucasian MS trio families, and analyzed using the transmission/disequilibrium test. No association with MS was found (rs1990760, P=0.45 and rs2068330, P=0.27). Similarly, no significant association was detected after stratification for HLA-DRB1*1501 carriers. Reasons that may explain this discrepancy between the original report and our study are discussed.
Subject(s)
Calcium-Binding Proteins/genetics , DEAD-box RNA Helicases/genetics , Ether-A-Go-Go Potassium Channels/genetics , Genetic Predisposition to Disease/genetics , Multiple Sclerosis/genetics , Cohort Studies , France , Genetic Variation , Genotype , Humans , Interferon-Induced Helicase, IFIH1ABSTRACT
SPG13, an autosomal dominant form of pure hereditary spastic paraplegia, was recently mapped to chromosome 2q24-34 in a French family. Here we present genetic data indicating that SPG13 is associated with a mutation, in the gene encoding the human mitochondrial chaperonin Hsp60, that results in the V72I substitution. A complementation assay showed that wild-type HSP60 (also known as "HSPD1"), but not HSP60 (V72I), together with the co-chaperonin HSP10 (also known as "HSPE1"), can support growth of Escherichia coli cells in which the homologous chromosomal groESgroEL chaperonin genes have been deleted. Taken together, our data strongly indicate that the V72I variation is the first disease-causing mutation that has been identified in HSP60.
Subject(s)
Chaperonin 60/genetics , Chromosome Mapping , Mitochondrial Proteins/genetics , Mutation/genetics , Spastic Paraplegia, Hereditary/genetics , Alleles , Blotting, Western , Chaperonin 10/genetics , Chaperonin 10/metabolism , Chaperonin 60/chemistry , Chaperonin 60/metabolism , Escherichia coli/genetics , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Female , Genetic Complementation Test , Humans , Male , Mitochondrial Proteins/metabolism , Models, Molecular , Molecular Sequence Data , Operon/genetics , Pedigree , Protein ConformationABSTRACT
Multiple sclerosis is a chronic inflammatory disease of the central nervous system with a genetic component. Until now, the more consistent association with the disease is found with the major histocompatibility complex, especially HLA-DRB1*1501-DQB1*0602 haplotype. In this report, we demonstrate the interaction of Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4 [CD152]) gene with DRB1*15 haplotype in multiple sclerosis genetic susceptibility. Our data were obtained from two European independent family-based studies including 610 multiple sclerosis family trios. Ann Neurol 2003;54:119-122
Subject(s)
Antigens, Differentiation/genetics , HLA-DR Antigens/genetics , Immunoconjugates , Multiple Sclerosis/genetics , Abatacept , Antigens, CD , CTLA-4 Antigen , Cohort Studies , DNA Primers/genetics , Genetic Predisposition to Disease , HLA-DR Serological Subtypes , Humans , Immunoblotting , Polymerase Chain Reaction , Polymorphism, Genetic/genetics , Promoter Regions, Genetic/geneticsABSTRACT
Multiple sclerosis (MS) is a demyelinating autoimmune disease with a strong yet complex genetic component. To date only the HLA-DR locus, and specifically the HLA-DR15 allele, has been identified and confirmed as influencing the risk of developing MS. Genomic screens on several datasets have been performed and have identified several chromosomal regions with interesting results, but none have yet been confirmed. We tested seven of the most-promising regions (on chromosomes 1p, 2p, 3p, 3q, 5q, 19q, and Xp) identified from several genomic screens in a dataset of 98 multiplex MS families from the United States and 90 multiplex MS families from France. The results did not confirm linkage to 2p, 3q, 5q, or Xp in the overall dataset, or in subsets defined by geographic origin or HLA-DR15 status. Regions on 1p34, 3p14, and 19q13 produced lod scores >0.90 in at least one subset of the data, suggesting that these regions should be examined in more detail.